Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

NCT00331500 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
287
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Alcon Research